Company intelligence / Profile preview

Jiangsu Tainuo Pharmaceutical

Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Jiangsu Tainuo Pharmaceutical is responsible for developing and commercializing ZILRETTA (triamcinolone acetonide extended-release injectable suspension) for osteoarthritis knee pain in Greater China, under license from Flexion Therapeutics. Clinical development and product registration in China ongoing as of 2020.

Therapeutic areas: Rheumatology
Modalities: Small molecule
Industry: Biotech

Partnerships

Flexion Therapeutics (ZILRETTA license)HK Tainuo Pharma (regional commercial/clinical development partner)

Beyond the preview

Go deeper on Jiangsu Tainuo Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiangsu Tainuo Pharmaceutical.

Explore the full profile